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\s=b\Acetyl levocarnitine hydrochloride has been reported to re-
tard dementia in patients with Alzheimer's disease. In a
double-blind, parallel design, placebo-controlled pilot study of
30 mild to moderately demented patients with probable
Alzheimer's disease, tests of memory, attention, language,
visuospatial, and constructional abilities were administered,
and the level of acetyl levocarnitine was measured in the cere-
brospinal fluid. Patients were then randomly assigned to re-
ceive acetyl levocarnitine hydrochloride (2.5 g/d for 3 months
followed by 3 g/d for 3 months) or placebo. After 6 months,
the acetyl levocarnitine group demonstrated significantly less
deterioration in timed cancellation tasks and Digit Span (for-
ward) and a trend toward less deterioration in a timed verbal
fluency task. No differences were found in any other neuropsy-
chological test results. A subgroup with the lowest baseline
scores, receiving acetyl levocarnitine, had significantly less de-
terioration on the verbal memory test and a significant in-
crease in cerebrospinal fluid acetyl levocarnitine levels com-
pared with those receiving placebo. These results suggest that
acetyl levocarnitine may retard the deterioration in some cog-
nitive areas in patients with Alzheimer's disease and stress the
need for a larger study of this drug.(Arch Neurol. 1992;49:1137-1141)
Acetyl levocarnitine hydrochloride is structurally similarto acetylcholine and appears to play a role in cerebral
glucose utilization and the stimulation of natural scavenger
functions to reduce oxidized radicals. It has been reported to
improve cognitive function in patients with Alzheimer's dis¬
ease (AD).14 Parnetti et al1 examined the mental state and be¬
havior in moderately to severely impaired patients with AD
after the intravenous infusion of acetyl levocarnitine hydro-
choloride (15 mg/kg over 5 minutes) in an open trial without
a placebo control group. They found significant improve¬
ment over baseline on a mental status examination at 10 and
60 minutes after drug administration. Guarnaschelli et al2
treated a group of elderly patients with cognitive impair¬
ment of unclear origin for 6 months with acetyl levocarnitine
hydrochloride (1.5 g/d by mouth) in an open trial. They
found a significant improvement over baseline on a mental
status examination, a rating of depression, and ratings on a
geriatric rating scale at 3 and 6 months. In a group of elderly
patients with mild cognitive impairment, Passeri et al3 found
improvement over baseline performance with acetyl levo¬
carnitine hydrochloride (2 g/d for 3 months) on timed at¬
tentional tests, a memory test, and "global performance." Re¬
sults of comparisons between drug and placebo groups were
not statistically significant. Mantero et al4 examined a group
of elderly patients with severe cognitive deficits and found
significant changes from baseline at the 3- and 6-month
follow-up assessments following treatment with acetyl levo¬
carnitine. However, no comparisons with a placebo group
were reported.
We examined the effect of acetyl levocarnitine in patients
with AD, as diagnosed by established criteria, who had a
mild to moderate degree of impairment. A placebo-
controlled double-blind parallel design was used.
SUBJECTS AND METHODS
Subjects
Thirty patients between 60 and 80 years of age who met
NINCDS-ADRDA5 criteria for AD were sequentially enrolled in
the study. Patients were recruited from a New York state-funded
clinic for dementia. They were living in the community and had
mild to moderate impairment, as measured by the Clinical
Dementia Rating6 of 1, and were taking no psychoactive medica¬
tions. All patients provided informed consent and had a regular
care giver who was available throughout the study to monitor
medication and to provide information about patient status.
Outcome Measures
Three types of outcome measures were made while investiga¬
tors were blind to drug or placebo assignment: cognitive tests,
functional status, and clinical impression.
A battery of neuropsychological tests was administered to as¬
sess cognitive function. This included the Verbal Selective Re¬
minding Test (SRT),7 with a 15-minute delayed recall and delayed
recognition components; the modified Mini-Mental State Exam¬
ination (MMS),8 which included Digit Span (forward and back¬
ward); the Logical Memory, Paired Associate, and Visual Repro¬
duction subtests from the Wechsler Memory Scale9; the Benton
Visual Retention Test10-Multiple Choice Version (Match and
Recognition tests); verbal fluency test for letter11; the category
naming test12; and a cancellation test that scores time and errors.13
For the Mini-Mental State Examination (MMS) described by Fol¬
stein et al,14 the result was estimated from the MMS.
Independent activities of daily living and quality of life were
assessed by the care givers using the Sickness Impact Profile(SIP)15 and the Squire's Memory Questionnaire (SMQ).16
The third outcome measure was the Clinical Global Impression(CGI), completed by a physician who rated the severity of the pa¬
tient's condition and then determined whether there was a change
from baseline. Patients were rated by the same physician at
8-week intervals.
Procedures
Patients were admitted to the General Clinical Research Center
of the Columbia-Presbyterian Medical Center, New York, NY, for
baseline assessments. These consisted of a neurologic examina-
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Table 1.—Neuropsychological Test Performance Scores in the Whole Group at Baseline andAfter 24 Weeks of Drug or Placebo*
Test
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*Values are mean (SD). SRT indicates Selective Reminding Test; mMMS,
tHigher scores reflect poorer performance.
modified Mini-Mental State Examination.
Table 2.—Neuropsychological Test PerformanceChange After 24 Weeks of Drug or Placebo*
Test

















































-0.3 (0.7) -0.2 (0.7)
3.2(9.8) 5.4(8.1)
6.6(11.7) 6.8(8.3)
"Values are mean (SD) change from baseline; negative scores reflect
poorer performance. SRT indicates Selective Reminding Test; mMMS,
modified Mini-Mental State Examination.
tlndicates significant difference by (test and by Wilcoxon Rank-Sum
test analysis (P<.05).
tion, a lumbar puncture, complete blood cell counts, routine blood
chemistry determinations, thyroid function tests, serum vitamin
B12 level measurement, a battery of neuropsychological tests, and
an assessment of independent function.
Patients were then randomly assigned to receive active drug or
placebo (with approximately half assigned to each group). Pa¬
tients, clinicians, and testers were blind to the drug or placebo sta¬
tus throughout the study. Acetyl levocarnitine hydrochloride was
prepared in 500-mg tablets and was administered at a dose of
2500 mg/d taken in three divided doses with meals (two tablets
in the morning, one tablet at midday, and two tablets in the
evening) for 12 weeks, followed by an increase to 3000 mg/d (two
tablets in the morning, two tablets at midday, and two tablets in
the evening) for an additional 12 weeks. The placebo group re¬
ceived an equal number of apparently identical tablets on the same
schedule. Patients were discharged with a supply of medication
and returned for outpatient visits at 4-week intervals. At each visit,
patients were seen by a physician, were asked about adverse
events, and underwent a brief neurologic examination, and a
month's supply of study medication was dispensed. Care givers
were asked to complete the SIP and SMQ at each visit. The most
recent supply of study medications was collected and counted to
assess compliance. The CGI was completed by the clinician based
on interviews with the patient and family members at 8-week
intervals.
Complete blood cell counts and routine blood chemistry deter¬
minations were repeated at 4 and 16 weeks. At 24 weeks, patients
returned to the General Clinical Research Center and all baseline
assessments were repeated. Another lumbar puncture was per¬
formed to assess the level of acetyl levocarnitine in the cerebro¬
spinal fluid (CSF).
The level of acetyl levocarnitine in the CSF was quantified ac¬
cording to the method of Pande and Caramancion.17 In brief, the
acetyl portion of the drug was stoichiometrically converted to ci¬
trate in the presence of radiolabeled carbon 14 oxaloacetate, car¬
nitine acetyltransferase, and citrate synthetase. The amount of ra¬
dioactivity formed was determined. The CSF samples from
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baseline and week 24 were stored at
—
70CC until the end of the
study to protect the blind design.
Data Analysis
Because this was a pilot study, the analysis was designed to
identify group differences on any measure and to examine safety.
Therefore, no attempt was made to adjust for multiple compari¬
sons. For each patient, the difference between baseline and 24
weeks was calculated for each cognitive and functional status mea¬
sure. Mean difference scores were generated for the drug and pla¬
cebo groups and comparisons were made with the use of a t test.
The CGI ratings for the drug and placebo groups were also com¬
pared with the use of a t test at each 8-week interval. In addition,
the Wilcoxon Rank-Sum test was used to compare the drug and
placebo groups on each measure. Difference scores were catego¬
rized as stable (aO) or deteriorated (<0), and drug vs placebo
group comparisons were examined with the use of  2 tests.
In a post hoc analysis, patients were divided into two sub¬
groups of equal size, according to baseline mMMS scores. Drug
vs placebo group comparisons were made within subgroups with
high and low mMMS scores. To examine the association between
CSF acetyl levocarnitine level and behavioral improvements, pa¬
tients in the drug group were also subdivided according to the
difference in CSF acetyl levocarnitine level between baseline and
24 weeks, and comparisons between these subgroups for cogni¬
tive measures were made with the use of t tests.
RESULTS
Three patients did not complete the trial. One became
agitated, required antipsychotic medication, and with¬
drew from the study. Another patient died of a cause un¬
related to the study medication. The third patient broke the
blind design of the study by having the study medication
analyzed. Data for the remaining 27 patients were ana¬
lyzed. Compliance with the medication regimen was
monitored and was found to be greater than 80% in all
subjects who completed the 6-month trial.
The drug and placebo groups were matched on demo¬
graphic variables and were equivalent on all measures at
baseline. The means (SDs) for the drug and placebo groups,
respectively, were as follows: age, 67.6 (6.0) and 71.2 (6.8)
years; education, 14.2 (3.4) and 15.2 (3.5) years; duration of
illness, 3.6 (1.3) and 3.0 (1.4) years; and estimated baseline
MMS score, 18.4 (4.0) and 19.1 (3.2).
Table 1 presents the baseline and 24-week performance
for the two groups on each neuropsychological test. There
was no significant difference between the two groups on
any measure at baseline. Tables 2 and 3 list the change from
baseline and the percentage of patients demonstrating sta¬ble or improved performance on neuropsychological tests
and measures of independent function. There was a
significant improvement in the drug group compared with
the placebo group on the cancellation task and Digit Span(forward). Borderline significance was demonstrated in
the verbal fluency test (P=.052) and the Logical Memory
subtest of the Wechsler Memory Scale (P=.052). There was
a significant difference (P<.05) on the CGI at 8 weeks, but
not at 16 or 24 weeks. There was no significant difference
in either the SIP or the SMQ. The CSF levels of acetyl
levocarnitine are shown in Table 4. There was no difference
between the drug and placebo groups in the CSF concen¬
tration of acetyl levocarnitine.
Results of Subgroup Analysis
In the subgroup with low baseline mMMS scores, less
deterioration was noted on the SRT in the drug group
compared with the placebo group (P<.05). Table 5 de-
Table 3.—Percent of Patients Demonstrating Stable orImproved Performance on Neuropsychological TestsAfter 24 Weeks*
% Stable or Improved
Test


























































*SRT indicates Selective Reminding Test; mMMS, modified Mini-
Mental State Examination.
tlndicates significant difference by  2 analysis (P<.05).
Table 4.—Acetyl Levocarnitine Levels in Cerebrospinal Fluid*
Baseline, ng/mL 24 wk, ng/mL Difference, ng/mLt
Drug(n=11) 1.54(0.36)
Placebo (n=14) 1.45(0.36)
Patients with mMMS score £35
Drug (n=6) 1.41 (0.16)
Placebo (n=6) 1.62 (0.30)
Patients with mMMS score >35
Drug (n=5) 1.64 (0.30)









312 (0.22)  
125 (0.32) J





"Values are mean (SD). mMMS indicates modified Mini-Mental State Examination, NS, not significant.
tNegative values indicate a decrease in acetyl levocarnitine level.
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Table 5.—Neuropsychological Test Performance Scores Low Baseline mMMS at Baseline and After 24 Weeks



































































































*Values are mean (SD). SRT indicates Selective Reminding Test;
tHigher scores reflect poorer performance.
mMMS, modified Mini-Mental State Examination.
scribes the baseline and 24-week performance for the two
groups on each neuropsychological test. There was no sig¬
nificant difference at baseline on any test. The mean change
in the SRT scores among those receiving drug was 1.4%
increase, while the placebo group demonstrated a mean
drop of 54% in memory test scores. This subgroup also
demonstrated improvement in verbal fluency, cancella¬
tions, and Digit Span (forward). Among those patients
with low mMMS scores, there was also a significant
increase in the CSF acetyl levocarnitine level at 24 weeks(P<.05) in the drug group compared with the placebo
group. There was no significant difference in neuropsy¬
chological test scores, CGI ratings, or CSF drug levels be¬
tween the drug and placebo groups among the patients
with high mMMS scores.
An additonal analysis compared subgroups of patients
with high and low CSF changes. There was a trend toward
improvement (P=.059) in the group with a high CSF drug
level compared with the group with a low CSF drug level
with regard to the time to complete the cancellation task.
Summary of Adverse Events
There were no changes in clinical hématologie or blood
chemistry results, and few adverse events were reported.
Four patients experienced adverse events that weredeemed "possibly related to study medication." Three pa¬
tients were in the placebo group, two of whom experienced
nausea and vomiting and one of whom experienced
abdominal discomfort. One patient in the drug group ex¬perienced nonspecific abdominal discomfort.
COMMENT
Our results could be interpreted to suggest that acetyl
levocarnitine may retard the deterioration of performance
on some tasks in patients with AD. The specific tasks
demonstrating a benefit were Digit Span (forward), timed
tasks of attention, and verbal fluency. Passeri et al3 also re¬
ported improvement in verbal fluency and in the comple¬
tion time of a target detection task.
Previous investigations involving acetyl levocarnitine
found no significant differences between drug and placebo
and suggested that the treatment period may need to be as
long as 6 months. In contrast, we found improvement in theCGI rating only at 8 weeks, with no benefit evident at 12 or
24 weeks.
We did not find a benefit in memory testing in the over¬
all analysis. This may be due to the small sample size in¬
volved in this pilot study. Results of the SRT were exam¬
ined to estimate the power of our study to detect a benefit
in memory with the use of methods described by Cohen.18
The effect size from group mean and proportional com¬
parisons ranged from 0.4 to 0.6. The group size in our study
yields power in the range of 18% to 33% for an  value of
.05 (two-tailed). Based on the effect size in our study, a
much larger sample size (30 to 45 per group) would be re¬
quired to achieve power of 80%.
The subgroup analysis suggested that memory, atten¬
tion, and verbal fluency appear to be most improved in
patients with moderate, rather than mild, impairment.
These patients also demonstrated a significant increase in
the CSF acetyl levocarnitine levels. In addition, post hoc
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analysis suggested a relationship between CSF acetyl
levocholine levels and improvement on a timed task. This
relationship between central measures of the drug and a
behavioral response to our knowledge has not been noted
before, perhaps because previous studies used lower
doses2 4 than were used in our study.Several reports have suggested an improvement in qual¬
ity of life,2-4 although this was not systematically measured.
We found no evidence of an improvement in quality of life,
as indicated by the absence of change on the SIP or SMQ.
The mechanism of action of acetyl levocarnitine is
unknown, but several possible mechanisms have been
postulated. It has been reported to activate choline acetyl-
transferase, increase high-affinity uptake, and have a spe¬
cific cholinomimetic effect.19 In addition, in rodent studies
it has been found to increase gamma-aminobutyric acid in
the substantia nigra.20 This is of particular interest given
our findings of benefits on timed tasks. Because disruption
of this system is associated with cognitive and motor
slowing, further studies might focus on patients with AD
with extrapyramidal involvement.
There have been no direct comparisons between acetyl
levocarnitine and other agents in the treatment of AD. Clin¬
ical trials of tetrahydroaminoacridine21-22 have yielded
mixed results, with the most recent studies suggesting nobenefit over placebo and substantial systemic side effects
and laboratory abnormalities. Our study, along with previ¬
ous reports,14 suggests that acetyl levocarnitine is relatively
safe, with no adverse systemic side effects and no changes
in liver enzyme or serum electrolyte levels.
Cholinergic agonists are relatively ineffective in improv¬
ing memory in patients with AD.23 Clinical trials with
cholinesterase inhibitors have yielded unclear results. Some
studies with oral physostigmine salicylate report no bene¬
fit24-25 and others demonstrate small, but statistically signif¬
icant, improvement in memory in patients with AD,26-27 par¬
ticularly when the drug is administered for relatively longperiods.27 We found a benefit on cognitive tests, but improve¬
ment in memory was seen in only a subset of patients.Our study was a pilot study designed to identify possible
directions for further evaluation of this drug under the rig¬
orous structure of a double-blind protocol. For this reason,
we used many outcome variables to spread the widest pos¬
sible net to capture any domain of change. Because our ob¬jective was to describe patterns of change to plan further in¬
vestigations, and not to make decisions about the efficacy of
this drug, we have presented our results unadjusted for mul¬
tiple comparisons, as recommended by Rothman.28
Overall, our study demonstrated mild improvement in
attention and timed tasks in patients with AD. Benefits in
memory were only seen in more impaired patients who
also showed an increase in CSF acetyl levocarnitine
concentrations. The relatively long exposure (ie, 6 months)
to this drug was an attempt to examine the effect on dis¬
ease progression. However, it is unknown whether the
specific outcome variables used herein were sensitive to
progression of AD. Future efforts should be targeted to
patients with moderate impairment and perhaps should
employ longer intervals of drug exposure.
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